Sector News

Less than a year in, 'action-oriented' Teva CEO Schultz has analysts impressed

June 27, 2018
Life sciences

Teva’s mega-cost-cutting drive hasn’t been popular with workers or its home country of Israel. Analysts, on the other hand, like what they’ve seen so far from the company’s new executives.

These days, Teva is “led by action-oriented leaders with a rapid and clear path to recovery,” Goldman Sachs’ Jami Rubin wrote in a note to clients after meeting with CEO Kåre Schultz and company last week. Compare that with ex-CEO Erez Vigodman’s C-suite, which Rubin characterized as “fairly reactionary and directionless,” and it makes for a “stark shift.”

So much so, in fact, that Rubin has recommended since December that investors buy Teva’s shares, despite the pricing pressure that continues to wreak havoc on the generics industry and the “limited track record” of the knockoff giant’s new management team.

“While still early in the turnaround phase, our confidence in the de-leveraging story and increasingly clear line of sight to growth (beginning in 2020) keeps us Buy rated,” she wrote.

Rubin isn’t alone. Earlier this year, Credit Suisse analyst Vamil Divan, M.D., upgraded Teva’s shares, pointing to “early signs of execution” on the $3 billion restructuring plan that’s set to claim 14,000 jobs.

Schultz, for his part, hasn’t tried to hide his own opinion of the way Teva’s former leaders handled the company. For one, they created a bloated corporate structure with too many layers, he said at January’s J.P. Morgan Healthcare Conference, and they grew through acquisitions in a way that Schultz found “very suboptimal from a cost-efficiency point of view.”

On top of that, “Teva used to focus on maximizing revenue in the generics business believing that if you just maximize revenue, everything will fall into place and you’ll get great profitability and so on,” Schultz said, stressing that instead, “you always need to maximize operating profit.”

Those philosophies helped Schultz, a veteran of Novo Nordisk and the former skipper at Lundbeck, land the Teva CEO job, along with a $17 million pay package the likes of which Teva’s top executives have never seen. And the way Rubin sees it, after Schultz has eased Teva’s debt and pared down costs, there will be plenty of opportunity for new products to chip in growth.

Neuro drug Austedo, for one, is “just scratching the surface” of a “huge” market for tardive dyskinesia, which Rubin thinks could make the product a blockbuster seller. And forthcoming migraine drug fremanezumab “could drive meaningful upside to EBITDA and cash flow for speedier debt repayment”—particularly if it launches this fall, as Teva executives expect.

By Carly Helfand

Source: Fierce Pharma

Related News

February 28, 2021

UCB taps Microsoft to accelerate drug discovery, clinical trials

Life sciences

The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.

February 28, 2021

GSK to close two UK antibiotics manufacturing sites

Life sciences

The planned closures come as GSK has agreed to sell its cephalosporins antibiotics business to Sandoz, a division of Swiss pharma firm Novartis, for as much as US$500m.

February 28, 2021

Colorcon launches TiO2-free supplement coating

Life sciences

“The launch of these new formulations provides the nutritional market with much-needed alternative coating systems that address clean label consumer preferences and are easy to implement,” says Kelly Boyer, vice president film coatings at Colorcon.

Send this to a friend